ArticleFrontiers in pharmacology2024

Case report: Therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective.

Xiaoli Mu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.